New Treating HER2-Positive Breast Cancer

New Treating HER2-Positive Breast Cancer.

For some women with old bust tumors, lower-dose chemotherapy and the drug Herceptin may help ward off a cancer recurrence, a redone study suggests. Experts said the findings, published in the Jan 8, 2015 New England Journal of Medicine, could put up for sale the first standard treatment approach for women in the dawn stages of HER2-positive breast cancer poto sexi raisa. HER2 is a protein that helps breast cancer cells greater and spread, and about 15 to 20 percent of breast cancers are HER2-positive, according to the US National Cancer Institute.

Herceptin (trastuzumab) - one of the newer, misnamed "targeted" cancer drugs - inhibits HER2. But while Herceptin is a ordinary treatment for later-stage cancer, it wasn't understandably whether it helps women with small, stage 1 breast tumors that have not spread to the lymph nodes view homepage. Women with those cancers have a somewhat low risk of recurrence after surgery and radiation - but it's hilarious enough that doctors often offer chemotherapy and Herceptin as an "adjuvant," or additional, therapy, explained Dr Sara Tolaney, of the Dana-Farber Cancer Institute in Boston.

The challenge, is balancing the unrealized benefits against the unimportant effects. So for the new study, her team tested a low-intensity chemo regimen - 12 weeks of a only drug, called paclitaxel - plus Herceptin for one year. The researchers found that women who received the drugs were greatly unlikely to see their heart of hearts cancer come back over the next three years. Of the 406 study patients, less than 2 percent had a recurrence.

There was no subdue group that did not receive chemo and Herceptin for comparison. But the results are "better than expected," said Dr Charles Shapiro, co-director of the Dubin Breast Center at Mount Sinai Hospital in New York City. Shapiro, who was not implicated in the study, said it's still not evident what the benefits could be in the longer term. "Three years of backup is short. Time will tell if there are tardy recurrences".

In other studies of women with small breast tumors (up to 1 inch across), recurrence rates over five years have ranged universally - from 5 to 30 percent. "With the regimen Euphemistic pre-owned in this study, there were very few recurrences and low toxicity. So it seems opposite number a reasonable option". Another oncologist not involved in the study agreed. "This is certainly an alternative for discussion," said Dr Paula Klein, also of Mount Sinai.

But that discussion does need to overlie the downsides. Herceptin is not an easy regimen. It's given by IV, usually once a week for a year, and the stock side effects include fever, nausea, vomiting and infection. There can also be more serious risks. Herceptin can bill the heart, sometimes leading to potentially life-threatening cardiomyopathy (an enlarged heart) or compassion failure, where the muscle begins to lose its pumping ability.

In this study, two women developed nerve failure. Their heart function normalized once they stopped Herceptin. another offspring is price. The one-year course of Herceptin costs roughly $64000, according to Genentech, the attendance that makes the drug and funded the current study. Still the shorter-term effects for women with dais 1 cancer appear "exceedingly favorable" sex pills free sri lanka. One question for future studies is whether those patients can aid from Herceptin alone, and forgo the chemo.

tag : herceptin cancer study women breast recurrence heart effects years

Post a comment

Private comment



Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Форма поиска
RSS ссылка
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья